Clinical Trials Sponsored by NMSG (Nordic Myeloma Study Group)

Total 26 results

Nordic Myeloma Study Group

Completed

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Multiple Myeloma

Denmark, Sweden, Norway
Nordic Myeloma Study Group

Unknown

Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients

Multiple Myeloma

Denmark
Nordic Myeloma Study Group
Nordic Cancer Union

Completed

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Multiple Myeloma

Denmark, Norway, Sweden
Stichting Hemato-Oncologie voor Volwassenen Nederland
European Myeloma Network; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM... and other collaborators

Active, not recruiting

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (HO95)

Multiple Myeloma

Sweden, Norway, Italy, Netherlands, Belgium, Switzerland, Australia, Denmark, Finland, Czechia, Turkey, Austria, Luxembourg, Hungary, Greece, Portugal
Oslo University Hospital
Nordic Myeloma Study Group

Active, not recruiting

Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. (CONPET)

Myeloma

Norway, Denmark, Sweden
Nordic Myeloma Study Group
Janssen-Cilag Ltd.

Completed

Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Multiple Myeloma

Norway, Sweden, Denmark, Finland, Iceland
Nordic Myeloma Study Group
Janssen-Cilag Ltd.

Unknown

Bortezomib and High-dose Melphalan at Myeloma Relapse

Multiple Myeloma

Denmark, Norway, Sweden
Henrik Gregersen
Nordic Myeloma Study Group

Unknown

Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support (CARFI)

Multiple Myeloma

Finland, Denmark, Sweden, Norway, Lithuania
Odense University Hospital
Danish Myeloma Study Group

Active, not recruiting

Quality of Life the Danish Multiple Myeloma Patients (QoL-MM)

Quality of Life | Multiple Myeloma

Denmark
Raija Silvennoinen
Takeda; Celgene; Nordic Myeloma Study Group

Active, not recruiting

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

Multiple Myeloma

Norway, Sweden, Finland, Lithuania
Oslo University Hospital
Helse Stavanger HF; St. Olavs Hospital; Nordic Myeloma Study Group

Active, not recruiting

REST - Replacing Steroids in the Transplant Ineligble (REST)

Multiple Myeloma

Norway, Denmark
Henrik Gregersen
Danish Myeloma Study Group

Terminated

Clarithromycin in Multiple Myeloma Induction Therapy (CLAIM)

Multiple Myeloma

Denmark
Henrik Gregersen
Danish Myeloma Study Group

Unknown

Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma (SUTRICA)

Multiple Myeloma | Infection

Denmark
Norwegian University of Science and Technology
The Research Council of Norway; Nordic Myeloma Study Group, Germany

Completed

Thalidomide to Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma

Norway
Stichting Hemato-Oncologie voor Volwassenen Nederland
German CLL Study Group; Nordic CLL Study Group

Recruiting

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER)

CLL/SLL

Netherlands, Denmark, Belgium, Germany
Cigdem Sahinbas YILMAZ
Turkish Society of Hematology Myeloma Study Group

Completed

Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma

Multiple Myeloma

Turkey
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
AGO Study Group
ARCAGY/ GINECO GROUP; Nordic Society of Gynaecological Oncology - Clinical...

Completed

Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST)

Ovarian Diseases | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Genital Diseases, Female

France, Germany, Denmark, Norway, Sweden, Finland
University of Göttingen
Nordic Lymphoma Group; German High-Grade Non-Hodgkin's Lymphoma Study Group

Unknown

Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP (A-CHOP-14)

Extranodal NK/T-cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Angioimmunoblastic Lymphadenopathy

Germany
AGO Study Group
GERCOR - Multidisciplinary Oncology Cooperative Group; Nordic Society of Gynaecological...

Completed

Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer (AGO-OVAR9)

Ovarian Cancer | Fallopian Tube Cancer

Norway, Germany, France, Denmark
European Mantle Cell Lymphoma Network
Nordic Lymphoma Group; HOVON - Dutch Haemato-Oncology Association; Lymphoma Study... and other collaborators

Unknown

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL (MCLelderly)

Lymphoma, Mantle-Cell

Czech Republic, Denmark, France, Germany, Italy, Netherlands, Poland
German CLL Study Group
AbbVie; Hoffmann-La Roche; Swiss Group for Clinical Cancer Research; Stichting... and other collaborators

Completed

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation (GAIA)

Chronic Lymphocytic Leukemia

Ireland, Germany, Israel, Austria, Belgium, Denmark, Switzerland, Finland, Sweden, Netherlands
German CLL Study Group
Cancer Trials Ireland; Stichting Hemato-Oncologie voor Volwassenen Nederland... and other collaborators

Active, not recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)

Chronic Lymphoid Leukemia

Spain, Ireland, Austria, Denmark, Israel, Norway, Germany, Switzerland, Italy, Belgium, Finland, Sweden, Netherlands
European Organisation for Research and Treatment...
NCIC Clinical Trials Group; Nordic Lymphoma Group; Lymphoma Trials Office; Australasian... and other collaborators

Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Lymphoma

France, Netherlands, Spain, Canada, Belgium, Australia, Sweden, United Kingdom, New Zealand, Hungary, Croatia, Czechia, Poland
Rigshospitalet, Denmark
Dana-Farber Cancer Institute; St. Jude Children's Research Hospital; European... and other collaborators

Completed

Second Malignant Neoplasms After Childhood ALL Therapy (PdL-SMN1)

Acute Lymphoblastic Leukemia

Denmark
GRADE Study Group
Bristol-Myers Squibb; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (GRADE)

Type 2 Diabetes | Comparative Effectiveness of Glycemia-lowering Medications

United States

Clinical Trials Sponsored by NMSG (Nordic Myeloma Study Group)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations